Please login to the form below

Not currently logged in

Amylin and Takeda discontinue obesity drug

Amylin Pharmaceuticals and Takeda Pharmaceutical Company discontinue pramlintide/metreleptin combined obesity treatment following a commercial reassessment

Amylin Pharmaceuticals and Takeda Pharmaceutical Company announced their decision to discontinue the development of pramlintide/metreleptin, a combination therapy for the treatment of obesity. 

This decision was reached after a “commercial reassessment” of the programme. This assessment took into account various factors including a revised development plan and the evolving dynamics within the obesity therapeutic area.

The drug comprised of pramlintide, an analogue of the natural hormone amylin, and metreleptin, an analogue of the natural hormone leptin. At the time of discontinuation, the drug was in its phase II stage, where it was an injection formula taken twice a day. 

Despite the discontinuation, Amylin and Takeda will continue to work together, and will continue to investigate the antibody-related laboratory finding with metreleptin treatment. Neither of the companies are expecting to revise the latest financial guide for their respective 2011 year. 

5th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...